Why Is MoonLake Immunotherapeutics Stock Soaring Monday? - MoonLake (NASDAQ:MLTX)

MoonLake reported durable one-year Phase 3 hidradenitis suppurativa data for sonelokimab and plans an FDA filing in September 2026.

Raccontata dabenzinga.com